SCHEMBL25275117

SCHEMBL25275117

COc1ccc(S(=O)(=O)n2cc(C=O)c(OC)c2-c2ccccc2F)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OXTR P30559 2/20 0.38
▸ AVPR1A P37288 2/20 0.38
▸ AVPR2 P30518 1/20 0.38
▸ ERN1 O75460 3/20 0.38
▸ EPHB4 P54760 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.35
▸ UBE2N P61088 1/20 0.35
▸ EIF2AK3 Q9NZJ5 1/20 0.35
▸ PTGS1 P23219 2/20 0.34
▸ PTGS2 P35354 2/20 0.34
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ TSHR P16473 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ PABPC1 P11940 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30287307 1.00 OXTR (0.38) OXTRAVPR1AAVPR2ERN1EPHB4
SCHEMBL28996379 0.88 ERN1 (0.41) OXTRAVPR1AERN1PTGS1PTGS2
SCHEMBL30287363 0.88 ERN1 (0.41) OXTRAVPR1AERN1PTGS1PTGS2
SCHEMBL31019973 0.85 CHRNB4 (0.37) ERN1KDM4EUBE2NKMT2AHTT
SCHEMBL25193028 0.85 CHRNB4 (0.37) ERN1KDM4EUBE2NKMT2AHTT
SCHEMBL31019967 0.84 ERN1 (0.40) ERN1KDM4EUBE2NPTGS1PTGS2
SCHEMBL25199320 0.84 ERN1 (0.40) ERN1KDM4EUBE2NPTGS1PTGS2
SCHEMBL31522099 0.84 AVPR2 (0.40) OXTRAVPR1AAVPR2EPHB4KDM4E
SCHEMBL26697786 0.84 AVPR2 (0.40) OXTRAVPR1AAVPR2EPHB4KDM4E
SCHEMBL26871192 0.83 AVPR2 (0.40) OXTRAVPR1AAVPR2EPHB4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084026-A1 NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF ILDONG PHARMACEUTICAL CO LTD (KR) 2025-03-13 — — US disclosed
US-20250042872-A1 NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME ILDONG PHARMACEUTICAL CO., LTD. (KR) 2025-02-06 — — US disclosed
CN-115884968-B Novel acid secretion inhibitor and use thereof 日东制药株式会社 2024-06-21 — — CN disclosed
WO-2023229323-A1 METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVE 일동제약(주) 2023-11-30 — — WO disclosed
WO-2023229322-A1 METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVES 일동제약(주) 2023-11-30 — — WO disclosed
WO-2023113458-A1 NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-06-22 — — WO disclosed
WO-2023113474-A1 NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME 일동제약(주) 2023-06-22 — — WO disclosed
CN-115884968-A Novel acid secretion inhibitor and use thereof 日东制药株式会社 2023-03-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084026-A1 NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF ABCG2, SLC7A1, SLC34A1 OXTR 3536/4885AVPR1A 407/4885AVPR2 303/4885
US-20250042872-A1 NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME SRM, SLC7A1, SLC20A1 OXTR 3456/4885AVPR1A 686/4885AVPR2 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback